Correction to "Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy"

Am J Hematol. 2025 Mar;100(3):542. doi: 10.1002/ajh.27551. Epub 2024 Dec 12.
No abstract available

Publication types

  • Published Erratum